Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $252.0M
- Net income
- -$220.8M
- Net margin
- -87.6%
Heavily indebted for what it earns.
- Total debt
- $589.4M
- Cash
- $336.5M
- Debt / equity
- 39.03
Comfortably covers what is due within a year.
- Current assets
- $675.0M
- Current liabilities
- $99.7M
- Current ratio
- 6.77
Consumes cash and must keep raising it.
- Operating cash flow
- -$220.6M
- Free cash flow
- -$220.9M
- FCF margin
- -87.6%
Some dilution over the past year.
- Shares outstanding
- 89.0M
- Share growth (1y)
- 3.1%
- Cash runway
- 18 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SNDX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 72.79 M | 64.86 M | 68.48 M | 45.87 M | 37.96 M | 20.04 M |
| Revenue Growth (YoY) | 91.76 % | 223.64 % | 791.68 % | 266.97 % | 984.51 % | — |
| Cost of Revenue | 3.21 M | 2.63 M | -1.57 M | 2.10 M | 1.28 M | 885.00 K |
| Gross Profit | 69.58 M | 62.23 M | 70.05 M | 43.77 M | 36.68 M | 19.16 M |
| SG&A Expense | 41.54 M | 37.59 M | 49.93 M | 44.92 M | 43.80 M | 41.03 M |
| R&D Expense | 68.04 M | 58.84 M | 78.64 M | 56.28 M | 62.23 M | 61.64 M |
| Operating Expenses | 109.58 M | 96.43 M | 132.60 M | 101.20 M | 106.03 M | 102.91 M |
| Operating Income | -39.99 M | -34.20 M | -62.55 M | -57.43 M | -69.35 M | -83.76 M |
| Pretax Income | -49.36 M | -42.67 M | -68.01 M | -60.72 M | -71.85 M | -84.85 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -49.36 M | -42.67 M | -68.01 M | -60.72 M | -71.85 M | -84.85 M |
| EPS (Basic) | -0.55 | -0.49 | -0.78 | -0.70 | -0.83 | -0.99 |
| EPS (Diluted) | -0.55 | -0.49 | -0.78 | -0.70 | -0.83 | -0.99 |
| Shares Outstanding | 88.99 M | 86.62 M | 86.62 M | 86.62 M | 86.34 M | 85.62 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.